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Abstract
The susceptibility of humans and animals to prion infections is determined by the virulence of the infectious agent, by
genetic modifiers, and by hitherto unknown host and environmental risk factors. While little is known about the latter two,
the activation state of the immune system was surmised to influence prion susceptibility. Here we administered prions to
mice that were repeatedly immunized by two initial injections of CpG oligodeoxynucleotides followed by repeated
injections of bovine serum albumin/alum. Immunization greatly reduced the required dosage of peripherally administered
prion inoculum necessary to induce scrapie in 50% of mice. No difference in susceptibility was observed following
intracerebral prion challenge. Due to its profound impact onto scrapie susceptibility, the host immune status may
determine disease penetrance after low-dose prion exposure, including those that may give rise to iatrogenic and variant
Creutzfeldt-Jakob disease.
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Introduction
Prion diseases, or transmissible spongiform encephalopathies
(TSE), are infectious neurodegenerative conditions that typically
lead to cognitive and motor dysfunction [1,2]. With the exception
of rare chronically presymptomatic carriers [3], prion diseases are
progressive, fatal, and presently incurable. Prions propagate
during the course of the disease and form aggregates containing
PrP
Sc, a misfolded, beta-sheet-rich isoform of the cellular prion
protein PrP
C, which is encoded by the PRNP gene [4,5]. Typical
neuropathological features include neuronal loss, astrogliosis and
spongiform changes [1,2].
In many instances, prion infections are acquired iatrogenically
or by oral uptake of prion-contaminated food [6]. For example,
bovine spongiform encephalopathy (BSE) has been transmitted
within cattle populations by prion-tainted meat and bone meal [7].
The ritual consumption of deceased relatives is the attributed
cause of the epidemic cases of Kuru in Papua New Guinea with
incubation periods exceeding 50 years [8]. Variant Creutzfeldt-
Jakob disease (vCJD) is believed to be caused by the consumption
of beef contaminated with BSE prions, as strongly suggested by
epidemiological, biochemical and neuropathological analyses as
well as transmission studies [9,10,11,12,13,14,15]. The association
between BSE and vCJD, together with the high number (at least
190,000) of BSE infected cows, mainly in the UK in the 1980s and
early 1990s, suggest a highly prevalent exposure of the European
population to BSE prions and have raised fears of an upcoming
vCJD epidemic. Fortunately, the incidence of vCJD remained
disproportionally low: roughly 200 human individuals succumbed
to vCJD until now and the incidence is declining.
The pivotal factors determining susceptibility to prion disease of
the exposed population remain largely unknown. Presence of the
cellular prion protein is certainly essential, since the absence of PrP
prevents disease in mice inoculated peripherally or intracerebrally
with prions [16,17], yet PrP
C expression alone is not sufficient to
sustain prion replication [18,19]. Intensive research has been
carried out to identify further risk factors, the major one being the
Met/Val polymorphism at codon 129 of the PRNP gene [20].
Almostall vCJDpatients todate havebeen foundtobe homozygous
for Met at this codon [5,21,22] and heterozygosity at codon 219
(219
Glu/Lys) is associated with decreased risk to develop sCJD [23].
Much less is known about any non-genetic risk factors. Analyses
of epidemiological data of different prion diseases, including
scrapie, BSE, and vCJD suggested that the risk for TSEs may be
age-dependent [24,25,26], but no further non-genetic risk factors
are known. It has been known for a long time that injections of the
immunomodulatory glucocorticosteroid prednisone prolonged
incubation time after intraperitoneal, but not intracerebral,
injection of scrapie-infected brain homogenate [27], suggesting
that the lymphoid system acts as a ‘‘Trojan horse’’ instead of a
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7160defense mechanism during scrapie pathogenesis. Indeed, prion
replication occurs in lymphoid tissues long before neuroinvasion
and subsequent detection in the central nervous system (CNS) [6].
Within secondary lymphoid organs, follicular dendritic cells
(FDCs) play a key role in peripheral prion replication and disease
pathogenesis. FDCs located within germinal centers express high
levels of PrP
C and accumulate PrP
Sc [28]. Maturation and
maintenance of FDCs depend on tumor necrosis factor alpha
(TNF-a) and lymphotoxins (LT-a and LT-b). Mice lacking TNF-
a, complement components and their receptors, LT-a, LT-b,o r
LT-b receptor are partially resistant to peripheral prion infection
[29,30]. Mice treated with an inhibitor of LT-b-receptor signaling
(LT-bR-Ig) displayed a reversible dedifferentiation of FDCs. This
leads to a decreased susceptibility to orally or intraperitoneally
administered prions [31,32,33]. In inflammatory conditions,
accordingly, extravasating immune cells enable prion replication
at the sites of chronic inflammation [34,35] and may even lead to
prion excretion [36]. Newborn mice whose immune system has
not fully matured were shown to display a strongly reduced
susceptibility to extracerebrally administered prions [37]. The
increase in susceptibility with age correlated with the immunocy-
tochemical detection of PrP
C on maturing FDCs [38].
Mature FDCs are unlikely to transport prions to peripheral nerve
terminals. However, the relative distance between FDCs and
peripheral nerves [39], and PrP
C expression in the peripheral
nervous system [40] determine prion neuroinvasion efficiency and
onset of terminal disease. Also, sympathectomy delays or prevents
scrapie followingintraperitoneal prion inoculation [41]. The precise
mechanisms of prion transport from prion replicating germinal
centers to peripheral nerves remain elusive. While germinal center
B-cells do not appreciably contribute to intrasplenic prion
trafficking [42,43], the identity of the crucial actuators of trafficking,
be they hematopoietic or stromal cells, or even subcellular particles,
remains to be determined. The presence of antigen presenting cells
(APCs) was described to be a prerequisite for lympho- and
neuroinvasion after peripheral prion infection [44,45,46,47,48],
although others have questioned their importance [49].
It was reported that repeated administration of CpG-containing
oligodeoxynucleotides (CpG-ODN) decreases the susceptibility to
prions [50]. Since CpG-ODN activate the Toll-like receptor 9
(TLR9), these surprising findings were interpreted as evidence that
activation of the innate immune system may be protective against
prions. However, we subsequently found that repeated injections
of CpG-ODN dramatically compromise morphology and func-
tionality of murine lymphoid organs [51]. Due to the mechanisms
discussed above, the immunosuppressive properties of CpG-ODN
are much more likely to account for the reported antiprion effects
than any conjectured immune activation [52].
Since the immune system has an essential role in peripheral
prion pathogenesis, we hypothesized that stimulation of the
immune system might increase the susceptibility towards periph-
erally administered prions [52]. To test this, laboratory mice
(C57BL/6) were confronted with a short-term challenge of CpG-
ODN followed by repeated immunization with bovine serum
albumin (BSA) and alum. This experimental protocol was devised
with the goal to broadly stimulate both the innate and the adaptive
components of the immune system for a protracted period of time.
Histological, hematological analysis as well as serum markers
identified changes indicative of moderate stimulation of the
immune system. By serial dilutions of the inocula, we could
indeed identify a dose of peripherally administered prions causing
scrapie in 50% of immunized mice whereas control mice remained
healthy. In contrast, repetitive immunization did not affect prion
susceptibility to intracerebrally administered prions.
Results
Stimulation of the immune system by repetitive
immunization
Starting 6 weeks prior to prion inoculation, wild-type mice
(C57BL/6) were immunized and repeatedly boosted with generic
antigens unrelated to prions, with the goal of achieving sustained
activation of immune cells and activation-related morphological
changes within lymphoreticular organs. A mixture of CpG-ODN,
bovine serum albumin (BSA) and alum was repeatedly injected
intraperitoneally during a period of two weeks (Fig. 1A). For the
following two weeks, treatment was suspended in order to prevent
damage to secondary lymphoid organs as observed following long-
term administration of CpG-ODN (data not shown). Mice were
then injected every other week for 20 weeks with BSA/alum.
At the time point of prion inoculation, selected animals were
sacrificed to evaluate organs and blood for histological, cytological,
and biochemical evidence of immune stimulation or inflammation,
respectively. When compared to age and gender-matched non-
immunized wild-type controls, immunized animals displayed
typical features of immune stimulation. Spleens of immunized
mice were significantly heavier, yet the concentration of splenic
PrP
C (weight/weight) remained unchanged (Fig. 1B), indicating
that the total amount of splenic PrP
C was increased. In peripheral
blood, chronic immunization resulted in significantly elevated cell
counts of erythrocytes, neutrophils, and monocytes. Lymphocyte
counts were marginally increased but did not reach statistical
significance (Fig. 1C).
We also investigated levels of various cytokines in sera. IL-6 was
elevated in mice with inflammation, whereas IL-12 (p70) was
reduced and IL-1a was unaltered. IFN-c was also increased
though not significantly (Fig. 1D), and TNF-a was below detection
limit in all animals analyzed (data not shown).
Splenic white pulp follicles appeared more densely packed upon
immunization (3.7860.31 and 7.8962.71 follicles/mm
2 in histo-
logical sections of non-immunized mice and immunized mice,
respectively; p=0.029). Immunized mice showed a significant
increase in density and size of PNA
+ germinal centers and Mfge8
+
follicular dendritic cell networks. In addition, we observed a
loosening of MOMA-1
+ metallophilic macrophage festoons in the
marginal zone following immunization as described previously
[51] (Fig. 2). Marginal zones appeared broader also in B220 and
CD21/35 immunostains. Accordingly, flow cytometry of spleno-
cytes showed a higher percentage of CD21/35
+CD23
2 marginal
zone B-cells in immunized mice than in controls (Fig. 2 and Fig. 3).
Mfge8 transcription is not only confined to germinal centers, but
also occurs in cells located in the marginal zone and were
suggested to represent FDC precursors [53]. However, in situ
hybridization did not identify any differences in Mfge8
+ cells
residing within the marginal zones of immunized and control mice
(Supplemental Figure S1). Instead, immunization increased the
prevalence of splenic GR1/Ly6g
+ granulocytes, as verified by
immunohistochemistry and flow cytometry (Fig. 2 and Fig. 3), and
increased the number of CD68
+ macrophages in splenic white
pulp follicles (Fig. 2). In contrast, the frequency of splenic CD11b
+
and CD11c
+ cells was unaffected (Fig. 3). Although total splenic
PrP
C protein concentration was unaltered, flow cytometry
revealed a slight yet significant increase in PrP
C surface expression
by splenic B220
+ and CD4
+ cells (Fig. 3).
Histological analysis of mesenteric lymph nodes (MLNs) showed
a trend towards increased numbers of lymphoid follicles (non-
immunized mice: 662.31; immunized mice: 11.7561.44 follicles/
lymph node section, p=0.11; Supplemental Figure S2A). Fur-
thermore, histology showed that immunized mice had a normal
CpG/BSA, Prion Susceptibility
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7160Figure 1. Repetitive immunization of wild-type mice. (A) Treatment scheme for immunization. Arrows denote the time points of injections of
CpG oligodeoxynucleotides and bovine serum albumin (BSA). Treatment included an induction (26t o24 weeks) and a maintenance phase (22t o
+18 weeks). (B–E) Selected immunized (i) and non- immunized mice (ni) were sacrificed at the time point of prion inoculation. (B) Relative spleen
weight and splenic PrP
C levels as determined by ELISA. Spleen derived from a PrP
C deficient mouse (Prnp
2/2) served as negative, spleen from a PrP
C
overexpressing mouse (tga20) as positive control. Hematological cell counts (C), serum levels of selected cytokines (D), and blood chemistry (E) (AP:
alkaline phosphatase; ASAT: aspartate amino transferase; GLDH: glutamate dehydrogenase; ALAT: alanine amino transferase) showed mild
polyglobulia and leukocytosis, as well as mild liver damage in repetitively immunized mice. Unpaired t-tests: (*) p,0.05; (***) p=0.001; (n.s.) not
significantly different.
doi:10.1371/journal.pone.0007160.g001
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lobular hepatitis with loss of hepatocytes and multifocal infiltrates
of lymphocytes, macrophages, eosinophils, and neutrophils
(Supplemental Figure S2B and data not shown). Hepatocellular
damage was confirmed by elevation of the liver enzymes glutamate
dehydrogenase (GLDH) and aspartate amino transferase (ASAT;
Fig. 1E). Serum amylase and alkaline phosphatase (AP) levels were
normal (Fig. 1E), suggesting that there was no damage to the
exocrine pancreas and the bile ducts. Finally, immunization
induced a mild peritonitis with macrophages and lymphocytes in
the peritoneum (Supplemental Figure S2C).
Increased prion susceptibility in immunized mice
Groups of mice (4#n#16) were inoculated intraperitoneally
(i.p.) or intracerebrally (i.c.) with low, medium or high doses of
prion infectivity as detailed in Fig. 4. Upon i.p. inoculation with
Figure 2. Splenic histology of immunized mice. (A) Spleens of non-immunized and immunized mice were analyzed at the time point of
inoculation by histology with hematoxylin-eosin (HE) and immunohistochemistry for B-cells (B220), complement receptors (CD21/35), metallophilic
marginal zone macrophages (MOMA-1), granulocytes (Ly6g), germinal center B-cells (PNA), FDCs (Mfge8), macrophages (CD68), and T-cells (CD3). The
overall splenic microarchitecture was preserved. Immunized mice showed broader marginal zones, some loosening of splenic MOMA-1
+ metallophilic
marginal zone macrophage festoons and a reduction of the density of MOMA-1
+ cells compared to non-immunized animals. Following immunization,
granulocytes (Ly6g) in the red pulp and macrophages (CD68) in the white pulp (indicated by dashed lines) were increased. (B) Densities and size of
PNA
+ germinal center B-cells and FDC networks (Mfge8) were also increased in immunized mice. Scale bars: 100 mm. Statistics was performed using
unpaired t-test, two-tailed.
doi:10.1371/journal.pone.0007160.g002
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succumbed to scrapie at 22368.2 days post inoculation (dpi).
When exposed to the same dose of prions, non-immunized
animals (n=16) remained scrapie-free for .500 dpi (Fig. 4). This
difference in survival was highly significant (p=0.0024, Fisher’s
exact test) and could have two non-exclusive explanations: 1)
immunization may increase the accumulation, spread, and/or
propagation of prions, or 2) immunization may promote the
progression of subclinical infection to clinically overt disease. To
study the latter possibility, we investigated non-immunized mice
that had received the same dose of peripherally administered
prions (10 ng) for subclinical signs of prion infection at 400 dpi.
Non-immunized mice did not display PrP
Sc in brains and spleens,
nor did they show any histological signs of prion disease such as
astrogliosis and microglial activation (Figs. 4–6). In addition, we
observed no difference in the time intervening between onset of
clinical signs and development of terminal scrapie (data not
shown). Therefore, repeated immunization of wild-type mice
increased the susceptibility to prion diseases by modulating prion
accumulation, spread, and/or propagation rather than by simply
affecting the onset of clinical signs.
While inducing scrapie in immunized mice, the dose of prion
inoculum utilized in the above mentioned experimental series was
insufficient to establish infection in non-immunized mice. We
therefore wondered what would happen after administration of a
dose that would induce a 100% attack rate in non-immunized
mice. We inoculated immunized and non-immunized mice i.p.
with a 30-fold higher dose of prions (300 ng RML6 brain
Figure 3. Splenic cell populations in immunized mice. Splenic cells were isolated and co-stained for PrP
C and B220, CD4, CD8, GR1, CD11c, or
CD11b; alternatively co-staining for CD21/35 and CD23 was performed. Results from representative samples are shown. Four mice per group were
analyzed. Numbers in the diagram indicate average percentages of cells 6 standard deviation. Statistical analysis was performed using unpaired t-
test, two-tailed. Significantly different percentages are labeled in the right lower scattergram with (*) p,0.05; (**) p,0.01; or (***) p,0.001.
doi:10.1371/journal.pone.0007160.g003
CpG/BSA, Prion Susceptibility
PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7160homogenate). No difference in the percentage of mice succumbing
to disease was observed: 7 of 8 mice in both groups (87.5%;
Fisher’s exact test p=1.0) developed terminal scrapie. This
indicates that immunization selectively lowers the size of the
minimal infectious dose, while it does not change the course of the
disease when larger doses are administered. Accordingly, the
incubation times in non-immunized (21965.7 dpi; n=8) and in
immunized mice (217610.3 dpi; n=8) inoculated with the highest
dose were similar to those in immunized mice that had received
the medium dose (22368.2 dpi, n=16; ANOVA p=0.3).
Therefore, stimulation of the immune system by repeated
immunization does not accelerate the general progression of the
disease, but rather renders mice susceptible to amounts of
peripherally administered prions that would be innocuous to
non-immunized wild-type mice.
We suspected that alterations in lymphoid organs mediate the
observed differences in susceptibility. As these events are not
thought to be relevant to CNS prion pathogenesis, we expected
that the difference in susceptibility would be abolished in
immunized versus non-immunized mice inoculated i.c. with
prions. The injection of 300 pg RML6 brain homogenate caused
disease in 2 of 8 mice (25%) in both groups. Survival curves did
not significantly differ (logrank test, p=1). A 30-fold higher prion
dose (9 ng RML6 brain homogenate) inoculated i.c. elicited an
attack rate of 4 of 4 (100%) in both groups. Although
immunization of wild-type mice strongly increased prion suscep-
tibility to i.p. administered prions, prion susceptibility remained
unchanged after i.c. inoculation. This emphasizes the decisive role
of peripheral immune system components in determining prion
susceptibility. Despite the absence of differential susceptibility,
there were slight differences in the incubation times at high and
medium dose of prion challenge. However, in both instances these
differences were not statistically significant (high dose: 9 ng i.c.;
non-immunized: 222632.8 dpi; immunized: 194617.4 dpi,
unpaired t-test p=0.18; medium dose: 300 pg i.c.; non-immu-
nized: 246/258 dpi; immunized: 229/244 dpi).
We then inoculated immunized and naı ¨ve mice i.p. with
0.33 ng RML6 homogenate, or i.c. with 10 pg RML6 homoge-
nate. None of these mice (immunized or naive) developed scrapie
or neurological signs up to 500 dpi. These data and the absence of
astrogliosis and microglia activation in brains of the non-
immunized mice (10 ng i.p. at 400 dpi) described above (Fig. 5)
argues against any neurotoxic effects of BSA/alum/CpG-ODN.
PrP
Sc distribution patterns and histopathological features
in terminally scrapie-sick mice
Brains of all mice developing clinical signs of scrapie were
investigated for histological features of prion disease, including
astrogliosis, spongiosis, PrP deposition and microglial activation
(Fig. 5). There were no differences in these histological hallmarks of
scrapie. In contrast, those non-immunized mice (n=4) inoculated i.p.
with prions (10 ng RML6 brain homogenate) that remained healthy
lacked any histological features of prion disease at 400 dpi. Although
the SAF84 antibody is commonly used to detect PrP aggregates, it is
notspecificforPrP
Sc.Therefore,inadditionweinvestigatedbrainsby
histoblot (Fig. 5) and immunoblot (Fig. 6). Both techniques
demonstrated the presence of PrP
Sc in all clinically scrapie-sick mice.
Similarly, spleens of terminally sick mice were investigated
histologically and biochemically by histoblot and immunoblot.
Figure 4. Survival of immunized (i) and non-immunized (ni) mice inoculated intraperitoneally (i.p.) or intracerebrally (i.c.) with
prions. While all mice inoculated i.p. or i.c. with a low dose of prions (0.33 ng i.p. or 10 pg i.c. RML6 brain homogenate; left panel) survived until 500
dpi, all mice inoculated i.c. with a high dose of prions (9 ng; right lower panel) died of scrapie. Seven of 8 mice (87.5%) inoculated i.p. with a high
dose of prions (300 ng) succumbed to scrapie independently of immunization (right upper panel). In the medium dose group (10 ng i.p. or 300 pg
i.c.; medium panels) there was no difference in survival rates in i.c. inoculated mice (75% in both groups). While non-immunized mice inoculated i.p.
with a medium dose of prions remained healthy, 50% of the immunized mice developed scrapie. Intercurrent deaths (not scrapie-associated)
occurred .400 dpi; time points are marked with a star above the curve. All brains of mice dying without clinical signs of scrapie were tested by
Western blot and did not contain PrP
Sc (data not shown).
doi:10.1371/journal.pone.0007160.g004
CpG/BSA, Prion Susceptibility
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compared to control (Fig. 7A), and PrP
Sc deposition pattern
(Fig. 7B). Besides, we could not detect an overt difference in the
PrP
Sc deposition as determined by immunoblot (Fig. 7C). As in
brains, PrP
Sc was not detectable in spleens of healthy non-
immunized mice at 400 dpi (n=4) that had received 10 ng RML6
brain homogenate i.p. (Fig. 7B and 7C).
No difference in splenic PrP
Sc deposition at 70 dpi
At 70 dpi there was no difference in PrP
Sc load in spleens of
immunized mice vs. non-immunized controls. PrP
Sc was detect-
able after sodium phosphotungstic acid (NaPTA) precipitation in
spleens of 1 of 4 immunized mice and of 1 of 4 non-immunized
mice (Supplemental Figure S3A). The early presence of PrP
Sc in
spleens (at 70 dpi) did not correlate with the observed difference in
prion susceptibility. PrP
Sc was below the limit of detection of the
NaPTA immunoblot technique in mesenteric lymph nodes of non-
immunized and immunized mice at 70 dpi (Supplemental Figure
S3A). Since it was previously reported that immune stimulation
might increase expression levels of PrP
C on blood cells [54], we
further analyzed PrP expression and cellular blood composition by
flow cytometry analysis. There was no significant increase of PrP
on CD19
+ B-cells, CD3
+ T-cells, or CD11b
+/CD11c
+ monocytes
in immunized vs. non-immunized mice. However, the overall PrP
expression on all live gated blood cells was slightly increased in
immunized vs. non-immunized mice, but this trend was not
significant (immunized: 30.462.81% of PrP positive white blood
cells; non-immunized: 25.361.57%; unpaired t-test p=0.12,
values in mean 6 standard error of the mean; Supplemental
Figure S3B and data not shown).
We did observe a significant increase in PrP signal on live-gated
blood cells in prion infected mice (immunized and non-immunized:
27.961.6% of PrP positive white blood cells) compared to non-
inoculated, naive mice (16.661.8%; unpaired t-test p,0.002;
Supplemental Figure S3B and data not shown). This rise in PrP
signal can either be attributed to increased protein expression,
decreased turn-over, or possibly accumulation of PrP
Sc on blood
cells. As previously shown by hematology, there was no significant
Figure 5. Brain pathology of terminally sick or asymptomatic mice. Immunized (i) and non-immunized mice (ni) inoculated intracerebrally
(i.c.) or intraperitoneally (i.p.) with medium or high dose of prions were analyzed by histology. HE stains and immunohistochemistry were performed
as indicated: astrocytes (GFAP), microglia (Iba1), PrP deposits (SAF84), showing astrogliosis, microglia activation, and prion protein deposition in
terminally sick mice from each of the experimental groups. Histoblot analyses detected PrP
Sc in the brains of all terminally sick mice with similar
distribution patterns. Non-immunized mice inoculated i.p. with a medium dose of prions remained healthy up to 500 dpi, and displayed much less
GFAP
+ astrocytes and Iba1
+ microglia cells, and lacked both PrP deposits (SAF84) and PrP
Sc (histoblot) at 400 dpi. Scale bars: histoblot=1 mm;
histology=100 mm.
doi:10.1371/journal.pone.0007160.g005
CpG/BSA, Prion Susceptibility
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was a trend towards an increase of CD19
+ B-cells in immunized, vs.
non-immunized mice (Supplemental Figure S3B).
Discussion
The outcome of encounters between a pathogen and its host is
determined by two sets of parameters: the intrinsic virulence of the
pathogen and the susceptibility of the host. Susceptibility is a
measure of the likelihood to contract disease after exposure to a
defined inoculum of a given pathogen. In addition to host-intrinsic
modifiers, susceptibility to most pathogens is profoundly influ-
enced by exogenous cofactors. Whereas immunodeficiencies
greatly increase susceptibility to most conventional pathogens,
theoretical considerations prompted us to investigate whether
susceptibility to prions may be enhanced by stimulation of the
immune system. Indeed, we have identified controlled, repetitive
immunization as an important host factor that dramatically
increases the susceptibility to peripherally administered prions.
Following injection of a low dose of prions, 50% of the immunized
mice developed scrapie while all non-immunized mice remained
scrapie-free for .500 dpi.
In most instances the likelihood of survival after exposure to
infectious agents or poisons is normally distributed, and therefore
cumulative dose-survival curves display sigmoidal responses with
subthreshold doses failing to elicit disease and high doses
plateauing towards maximal effects. As a consequence, variations
in host susceptibility are typically visible only within a limited
range of doses. Here we tested three different doses of prions in
immunized and non-immunized mice. The lowest dose led to
100% survival, whereas the highest dose led to 12.5% (i.p.) and
0% (i.c.) survival, in both groups. The medium dose of
Figure 6. PrP
Sc in brains of terminally sick or asymptomatic mice. Immunized (i) and non-immunized mice (ni) inoculated (A)
intraperitoneally (i.p.) or (B) intracerebrally (i.c.) with medium or high doses of prions were analyzed by Western blots for the presence of PrP
Sc. Brain
homogenates were analyzed with (+) and without (2) previous proteinase K (PK) treatment as indicated. Homogenate derived from a terminally
scrapie-sick mouse served as positive control (pos ctr), and healthy wild-type mouse tissue as negative control (neg ctr), respectively. Molecular
weights are indicated on the left side of the blots. All terminally sick mice showed considerable amounts of PrP
Sc in the brain. In contrast, non-
immunized mice inoculated i.p. with a medium dose of prions [i.p. medium (ni)] lacked PrP
Sc.
doi:10.1371/journal.pone.0007160.g006
CpG/BSA, Prion Susceptibility
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rate of 50% in immunized mice only, which nominally
corresponds to one LD50 unit (dose causing death in 50% of
the exposed hosts) and to the turning point of the postulated
sigmoid response curve. Therefore, in this paradigm the medium
dose allowed for optimal sensitivity in the identification of
immunization as a factor altering prion susceptibility.
Treatment with complete Freund’s adjuvant (CFA) was
reported to prolong survival of prion-inoculated mice, irrespective
of whether the challenge was i.c. or i.p. [55]. These results implied
that CFA treatment might have a therapeutic effect in experi-
mental scrapie, possibly by reducing the rate of PrP
Sc accumula-
tion in the brain. In our experiments we did not detect any
influence on susceptibility to i.c. administered prions, and a
sensitizing effect after peripheral prion administration. Possible
explanations for this discrepancy are (1) the different agents and
protocols (site of injection, frequency) used for immunization and
(2) the different titers of prion inocula applied.
Another study reported that transient systemic inflammation
induced by i.p. administration of LPS acutely exacerbates
cognitive and motor symptoms after inoculation with the mouse-
adapted ovine prion strain Me7 and accelerates disease progres-
Figure 7. Histology, histoblots, and Western blots of spleens from terminally sick or asymptomatic mice. (A) Spleens of immunized (i)
and non-immunized mice (ni) inoculated intraperitoneally (i.p.) with medium or high dose of prions were analyzed by histology. Histological and
immunohistochemical stains were performed as indicated. MOMA-1
+ cells were reduced in immunized mice. All terminally sick mice of the various
experimental groups carried PrP
Sc in their spleens as shown by histoblot (B) and confirmed by Western Blot (C). Asymptomatic, non-immunized mice
inoculated i.p. with a medium dose of prions [i.p. medium (ni)] were killed at 400 dpi. No PrP
Sc was detectable by histoblot analysis (B) and Western
blot analysis (C). Controls and abbreviations are as in Fig. 6. Scale bars: histoblot=1 mm; histology=200 mm.
doi:10.1371/journal.pone.0007160.g007
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i.c. with prions became terminally sick slightly earlier than
controls. Although we investigated the influence of other
immunizing agents on another prion strain, our finding might
well be explained by an acceleration of disease progression as
suggested [56]. In contrast, we focused on differences in disease
susceptibility rather than disease onset and progression.
Another study investigated the impact on experimental
autoimmune encephalomyelitis (EAE) on prion susceptibility and
incubation time. Increased prion susceptibility was observed after
low dose i.c. inoculation [57], whereas we could not observe any
change in prion susceptibility after low dose i.c. inoculation. This
may point to additional EAE-related effects on prion transport,
such as e.g. disturbance of the blood-brain barrier.
It was previously reported that susceptibility of mice to BSE and
RML5 prions is not affected by the activation of dendritic cells
[49]. Also, we previously found that chronic lymphofollicular
inflammation of kidney, pancreas, and liver did not overtly alter
susceptibility [34]. However, in all of these studies the scrapie
attack rates were 100% in both the experimental and the control
groups of mice, suggesting that the size of the prion inocula have
precluded the sensitive detection of susceptibility shifts. This
interpretation is congruent with our finding of indistinguishable
attack rates in non-immunized and immunized mice peripherally
exposed to a relatively large inoculum (300 ng of brain
homogenate).
It had been previously reported that repeated injection of CpG-
ODN protects mice from prion infections [50], suggesting
beneficial effects of immune hyperactivity on prion susceptibility,
but this treatment was subsequently found to disturb micro-
architecture and functionality of lymphoid organs [51]. Therefore,
the interpretation of the current findings crucially relies on the
intactness of the immune system. Indeed, histology, hematology,
and serum chemistry failed to identify immuno-suppressive
consequences of the herein described treatment. Our data add
weight to the conjecture that immunization increases susceptibility
to prions and that the previously described protective effects were
caused by immuno-disruption rather than by stimulation of the
immune system.
As a consequence of the immune stimulation protocol, we
observed moderate hepatitis. This might be explained by the
hepatotoxic effects of IL-6, which was increased in serum of
immunized mice as previously reported [58]. The increased
susceptibility of immunized mice was restricted to peripheral prion
exposure, and was not observed after i.c. prion inoculation.
Evidently immune modulation appears to affect the speed and/or
the extent of prion replication outside but not within the CNS.
This suggests that CNS cells are constitutively competent for prion
replication, whereas peripheral sites (which may comprise not only
lymphoid compartments but also e.g. peripheral nerves) appear to
be susceptible to immunological modifiers.
The precise mechanisms by which repetitive immunization
increases prion susceptibility remain unknown. Any of the steps
involved in peripheral prion spread, including transfer of prions
to lymphoid tissues, prion accumulation and propagation within
lymphoid tissues, and prion transfer from lymphoid tissues
to structures of the nervous system, might be affected by
immunization.
The kinetics of PrP
Sc accumulation in lymphatic organs might
arguably play an important role in susceptibility to peripheral
prion administration. While all terminally sick mice carried PrP
Sc
in the spleen, PrP
Sc was undetectable in spleens of all mice that
remained healthy. At early time points (70 dpi), before
neuroinvasion had taken place [17], there was no difference in
splenic PrP
Sc load. Hence, chronic inflammation determines the
susceptibility towards prions by a mechanism that is independent
of the early splenic PrP
Sc accumulation. Also, the absence of PrP
Sc
from MLNs at 70 dpi suggests that at least in early stages of
disease, and under the conditions studied here, MLNs do not play
an essential role in prion pathogenesis.
The absence of PrP
Sc from spleens at $400 dpi despite its
presence at earlier stages suggests the existence of a splenic prion
clearance mechanism. Maybe repetitive immunization of the
immune system facilitates neuroinvasion by reducing splenic prion
clearance. The reduced numbers of MOMA-1
+ marginal zone
macrophages in immunized mice could contribute to an inhibited
prion clearance. MOMA-1
+ cells play an important role in
capturing blood borne antigens [59]. Involvement of splenic
macrophages in prion clearance in the early phase of infection has
been reported, and it was even proposed that marginal zone
macrophages are precisely involved in this process [60]. This
suggests that a decreased prion uptake by MOMA-1
+ cells might
lead to a more efficient prion translocation into germinal centers in
immunized mice in our study. In this context, it has previously
been suggested that CpG-ODN treatment inhibits prion clearance
by microglia cells in vitro [54].
We have found an increase in marginal zone B-cells in
immunized mice. It is conceivable that alterations in the number
of marginal zone B-cells in combination with a decreased number
of MOMA-1
+ cells might enhance prion uptake into the germinal
centers, thereby influencing prion susceptibility. APCs were
proposed to either support prion clearance or to accomplish prion
transport [44,45,46,47,48,49]. Immunohistochemical as well as
flow cytometry analysis of blood and spleen from immunized mice
did not reveal a significant change of CD11c
+ or CD11b
+ APCs.
Therefore, it is very unlikely that quantitative changes in APCs
would contribute to the observed increase in prion susceptibility.
FDCs play an important role in prion replication and are known
to co-localize with PrP
Sc. In our study, there was an increase in
size and density of FDC networks following immunization. This
might well explain the increased susceptibility in immunized mice.
Alternatively, chronic stimulation of the immune system may alter
the transfer of prions from lymphoid organs to the nervous system.
This transfer has previously been shown to be rate-limiting in
prion pathogenesis, involving FDCs within germinal centers and
tyrosine hydroxylase (TH) positive sympathetic nerve endings.
Since immune activation can alter splenic innervation [61], we
wondered whether the distance between FDCs and terminal nerve
endings was changed, contributing to the increased prion
susceptibility of immunized mice. However, staining for tyrosine
hydroxylase failed to show altered distances between nerve endings
and follicles (data not shown).
Altered PrP
C levels in secondary lymphoid organs can
potentially impact prion susceptibility or prion incubation time.
Immunization in this study did not alter the overall splenic PrP
C
levels as determined by ELISA. Interestingly, by flow cytometry, a
slight increase in PrP
C cell surface expression was detected on
splenic B- and CD4
+ T-cells in immunized mice. We cannot
exclude that this slightly increased PrP
C expression on either of the
two cell types contributes to increased susceptibility. However,
previous studies have shown that PrP
C neither on B- nor on T-cells
alone suffices for efficient prion replication [18,62]. Therefore, we
presume that PrP
C levels on B- and T-cells are not the
susceptibility determining factors in our study.
CpG-ODN and LPS treatment can increase the cell surface
level of PrP
C on macrophages, and it has been suggested that
macrophages can replicate prions transiently after stimulation with
LPS or CpG-ODN [54]. The conditions used here for
CpG/BSA, Prion Susceptibility
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blood cells or splenic CD11c
+ or CD11b
+ cells. Therefore, it is
unlikely that PrP levels on white blood cells or antigen presenting
cells within the spleen determined prion susceptibility in our study.
We have found an increased density of splenic granulocytes
following immunization. This might have an impact on prion
susceptibility. Since the role of granulocytes in prion pathogenesis
is unknown, no definite conclusions can be drawn. Similarly, the
impact of CD68
+ cells appearing in the white pulp follicles of
immunized mice and its effect on peripheral prion replication
remain unknown. Alum, which was used as an immunization
adjuvant in our study, was recently shown to induce influx of
monocytic dendritic cells into the peritoneum. This Nalp3-
dependent influx [63] may conceivably represent a mechanism
for efficient transfer of prions to secondary lymphoid organs. It will
be interesting to test whether interference with this pathway
modulates prion susceptibility.
In summary, we conclude that either (1) increased density and
size of FDC networks in splenic germinal centers, (2) decreased
clearance of prions by changing the cellular compartment of the
marginal zone (e.g. marginal zone macrophages, marginal zone B-
cells), or (3) both, are most likely responsible for increased prion
susceptibility upon immunization. In the light of the above results, it
will be of interest to determine whether stimulation of the immune
system may contribute to the individual susceptibility of humans
towards prions. States of chronically stimulated immune system are
common in humans, and can occur e.g. in chronic infectious
diseases, autoimmune disorders, and allergies. Exposure to BSE
prions is the assumed cause of vCJD, yet it is not known which
factors determined that some unfortunate individuals among the
European population developed vCJD while most others remained
healthy. Epidemiological retrospective and prospective studies may
help clarifying whether particular immune stimuli correlate with the
likelihood to contract vCJD or other acquired prion diseases.
Materials and Methods
Mice and scrapie inoculation
Female wild-type (C57BL/6) mice were obtained from Harlan,
NL and maintained under specific pathogen-free (SPF) conditions.
Housing and experimental protocols were in accordance with the
Swiss Animal Protection Law and mice were held in compliance with
t h er e g u l a t i o n so ft h eV e t e r i n a ¨ramt, Kanton Zu ¨rich. Mice were
infected intraperitoneally (i.p.) with 100 ml brainhomogenate derived
fromterminallyscrapiesickCD-1mice,homogenizedinPBS/0.32M
sucrose, or intracerebrally (i.c.) with 30 ml brain homogenate.
Different doses of prions derived from a RML6 infected terminally
sick wild-type mouse were injected intraperitoneally (i.p.) or
intracerebrally (i.c.) (i.p. doses: 0.33 ng, 10 ng, 300 ng; i.c. doses:
10 pg, 300 pg, 9 ng brain homogenate). Mice were euthanized at 0,
70 and 400 dpi or when terminally scrapie sick.
Repetitive immunization
Repetitive immunization was performed in female wild-type
(C57BL/6) mice by repeated injections of CpG-ODN and BSA/
alum. BSA was diluted in 200 ml of freshly prepared Al(OH)3 to a
final concentration of 50 mg BSA per injection per mouse as
described [43]. Intraperitoneal injections of either 30 mg CpG-
ODN (Coley pharma, ODN 1826) or BSA/alum were performed
as indicated in Fig. 1A, starting 6 weeks prior to prion inoculation.
Western blot analysis and NaPTA precipitation
Tissue homogenates (brain; spleen) were adjusted to 8 mg/ml
protein, and treated with proteinase K (20–50 mg/ml, 30 min,
37uC). 50 mg of total protein was loaded onto a NuPAGEH Novex
12% Bis-Tris Gel (Invitrogen) and separated. Proteins were then
transferred to nitrocellulose membrane (see below). For detection
of PrP
Sc in spleen homogenates NaPTA (sodium phosphotungstic
acid) precipitation was performed. 10% spleen homogenates were
prepared in PBS on ice. Cellular debris was removed by
centrifugation at 500 g for 1–2 min. The resulting supernatant
was adjusted to 500 ml with PBS, and mixed 1:1 with 4% Sarkosyl
in PBS. Samples were incubated for 15 min at 37uC under
constant agitation. Benzonase and MgCl2 were added to a final
concentration of 50 U/ml and 1 mM respectively, and incubated
for 30 min at 37uC under continuous agitation. Further, samples
were digested with 30 mg/ml proteinase K (PK) for 60 min at
37uC with agitation and pre-warmed NaPTA stock solution
(pH 7.4) was added to a final concentration of 0.3% and the
sample was incubated at 37uC for 30 min with shaking, followed
by centrifugation at 37uC for 30 min at 14.000 g in an Eppendorf
microcentrifuge. The pellet was resuspended in 30 ml 0.1%
Sarkosyl in PBS and the sample was heated at 95uC for 5 min
in SDS-containing loading buffer before loading onto NuPAGEH
Novex 12% Bis-Tris Gel (Invitrogen). All gels were transferred to
nitrocellulose (Schleicher & Schuell) using XCell II Blot Module
(Invitrogen). Membranes were blocked with TBST containing 5%
non-fat milk, decorated with monoclonal antibody POM1 [64,65]
followed by incubation with the secondary anti-mouse IgG1
(Zymed) and visualized by enhanced chemiluminescence (ECL,
Socochim, Pierce).
Histology, immunohistochemistry, and histoblot
Paraffin sections (2 mm) and frozen sections (5 or 10 mm) of
various organs were stained with hematoxylin-eosin. Antibodies
raised against the following antigens were used for immunohisto-
chemistry: FDC-M1 (Mfge8) for mature FDCs (clone 4C11; 1:50;
Becton Dickinson), B220/CD45R for B-cells (Pharmingen; 1:400),
CD35 for CR1 (clone 8C12, Pharmingen, San Diego, CA; 1:100),
CD3 for T-cells (clone SP7, NeoMarkers; 1:300), F4/80 for
macrophages (Serotec; 1:50), PNA for germinal center B-cells
(Vector L-1070; 1:100), MOMA-1 for metallophilic marginal zone
macrophages (BMA, Augst, Swizerland; 1:50), GFAP for astro-
cytes (DAKO, Carpinteris, CA; 1:300), and Iba-1 for microglia
(WAKO; 1:2500).
PrP stains were performed on formalin-fixed brain tissues
treated with concentrated formic acid to inactivate prions and
postfixed again in formalin. Subsequently, tissues were embedded
in paraffin. After deparaffination, sections (2 mm) were incubated
for 6 min in 98% formic acid and washed in distilled water for
30 min. Sections were heated to 100uC in a steamer in citrate
buffer (pH 6.0) for 3 min, and allowed to cool down to room
temperature. Sections were incubated in Ventana buffer and stains
were performed on a NEXES immunohistochemistry robot
(Ventana instruments, Switzerland) using an IVIEW DAB
Detection Kit (Ventana). After incubation with protease 1
(Ventana) for 16 min, sections were incubated with anti-PrP
SAF-84 (SPI bio; 1:200) for 32 min. Sections were counterstained
with hematoxylin. Histoblot analysis was performed as described
[66]. Image acquisition was performed on an Axiophot-micro-
scope (Zeiss) equipped with a JVC digital camera (KY-F70;
3CCD).
In situ hybridization
Digoxigenin (DIG)-labeled Mfge8 riboprobe was obtained by
transcription of pBluescript II KS+ (Stratagene) containing the
open reading frame of Mfge8 and using a DIG RNA labeling kit (Roche).
ISH was performed on spleen cryosections. Sections were fixed in
CpG/BSA, Prion Susceptibility
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prehybridization, 200 ng/ml of DIG-labeled RNA probe was
added to the hybridization buffer and incubated at 72uC
overnight. DIG-labeled probes were detected by anti-DIG–
alkaline phosphatase Fab-fragments (Roche). Cell nuclei were
stained with DAPI (49,6-Diamidine-29-phenylindole dihydrochlo-
ride; Roche).
RNA isolation from spleen and real-time PCR analysis
RNA isolation buffer (RLT; Qiagen) was added to flash frozen
spleens prior to homogenization (Medic tools). RNA was purified
using RNeasy (Qiagen) as described by the manufacturer.
Synthesis of cDNA was performed with QuantiTect, Reverse
Transcription kit (Qiagen). Samples were analyzed by real-time
PCR using QuantiFast SYBR Green PCR kit (Qiagen) and
7900HT (Fast Real-Time PCR systems; Applied Biosystems). The
following primer combinations were used [forward primer (FW),
reverse primer (RV)]: Mfge8 FW: 59-ATA TGG GTT TCA TGG
GCT TG-39; Mfge8 RV: 59-GAG GCT GTA AGC CAC CTT
GA-39; GAPDH FW: 59-CCA CCC CAG CAA GGA GAC-39;
GAPDH RV: 59- GAA ATT GTG AGG GAG ATG CT-39
PrP
C sandwich ELISA
96-well plates were coated with 20 ng of purified POM1
antibody overnight at 4uC. Plates were washed with PBS
containing 0.1% (vol/vol) Tween 20 (PBST), and blocked with
5% Top-Block (Fluka) in TBST for 2 h at room temperature (RT).
After washing, plates were incubated with 50 ml of spleen
homogenates containing 500 mg/ml total protein in sample buffer
(1% Top block in PBST). The total protein concentrations of the
spleen homogenates were determined using a standard colorimet-
ric assay based on bicinchoninic acid (BCA, Pierce). Each sample
was analyzed in triplicates. For the standard curve, serially diluted
recombinant mouse PrP23-230 in PBST containing 1% Top Block
was used. After 1 h at RT plates were washed extensively and then
probed with biotinylated POM2 [64,65] at a concentration of
200 ng/ml in PBST containing 1% Top Block, for 1 h at room
temperature. After washing, plates were incubated with horserad-
ish peroxidase conjugated Avidin (1:1000 dilution, BD-Pharmin-
gen) for 1 h at RT. Plates were developed with Stabilized
Chromogen SB02 (Biosource). The chromogenic reaction was
stopped by adding the same volume of 0.5 M H2SO4. Optical
density was measured at 405 nm. The PrP
C concentration in each
sample was calculated according to a standard curve derived from
the values of recombinant PrP.
Fluorochrome labeling
1 mg of Cy5 NHS ester (Amersham Biosciences; Cat.
No. PA15101) was dissolved in 1 ml (conc. 1 mg/ml) water-free
DMSO. 1 ml of the POM2 antibody [64,65] (conc. 2 mg/ml) and
of 0.5 M borate buffer (pH 8.0) leading to an antibody
concentration of 1.81 mg/ml. 2 mg POM2 (1.1 ml) were used
for the labelling reaction (Dye/antibody ratio=2.5/1). 2 mg
POM2 were mixed with 24.80 ml of Cy5 dye (31.25 nmol). The
Cy5 dye was added to the antibody while vortexing and further on
incubated under permanent agitation for 1 h at RT (light
protected). The unincorporated Cy5 dye was removed in a size-
exclusion column and the labeled antibody was dialyzed against
2 l of PBS over night.
Flow cytometric analysis
Splenic cells or blood cells were isolated and incubated with
primary antibodies: POM2-Cy5 (1:250), FITC- or PE-labeled
anti-CD11b antibody, FITC- or PE-labeled anti-CD11c antibody,
PE-labeled anti-CD19 antibody, FITC-labeled anti-B220 anti-
body, PE-labeled anti-Ly6G antibody, PE-labeled anti-CD8, PE-
labeled anti-CD3 antibody (all 1:100, Pharmingen), PerCP-labeled
anti-CD4 (1:750), or FITC-labeled anti-CD21 and PE-labeled
anti-CD23 (1:100 and 1:250, respectively). Erythrocyte lysis was
performed using BD FACS
TM Lysing Solution. Cells were washed
with PBS containing 2% FCS and live gated blood cells were
further analyzed with a flow cytometer (DAKO or BD Biosciences)
and FlowJow software program.
Supporting Information
Figure S1 In situ hybridization for Mfge8 mRNA. Spleens of
non-immunized and immunized mice were analyzed at the time
point of inoculation by in situ hybridization for Mfge8 mRNA.
Consecutive sections were hybridized with Mfge8 antisense (AS)
and control sense probe (S) as well as DAPI stains. Scale
bar=100 mm.
Found at: doi:10.1371/journal.pone.0007160.s001 (7.90 MB TIF)
Figure S2 Histology of mesenteric lymph nodes, various organs,
and peritoneum of immunized and non-immunized mice. (A)
Mesenteric lymph nodes (MLNs) were analyzed at the time point
of inoculation by histology and immunohistochemistry. Stains and
immunohistochemistry were performed as indicated: HE, B-cells
(B220), germinal center B-cells and FDCs (CD21/35), FDCs
(Mfge8), germinal centers (PNA) and metallophilic marginal zone
macrophages (MOMA-1). (B) Additional organs were analyzed.
While lung, kidney, and pancreas displayed a normal architecture,
liver showed lobular hepatitis with loss of hepatocytes and
multifocal infiltrates of T-lymphocytes (CD3), macrophages (F4/
80), eosinophils, and neutrophils. (C) Immunized mice showed
infiltrates of T-cells (CD3) and macrophages (F4/80) in the
peritoneum, demonstrating peritonitis. All scale bars=100 mm.
Found at: doi:10.1371/journal.pone.0007160.s002 (7.43 MB TIF)
Figure S3 PrP in spleens, mesenteric lymph nodes (MLNs), and
on blood cells of inoculated mice at 70 dpi. Mice were inoculated
i.p. with a medium dose of prions and analyzed at 70 dpi. (A)
NaPTA-enhanced Western blots of spleen and MLN homoge-
nates. We detected PrP
Sc in spleens of 1 of 4 mice in both, the
immunized (i) and non-immunized (ni) group. Controls and
abbreviations are as in Fig. 6. No PrP
Sc deposition was detectable
in MLNs of the same mice by NaPTA-enhanced Western blotting.
(B) Flow cytometry analysis of white blood cells from immunized
and non-immunized mice inoculated i.p. with prions, as well as
non-inoculated, non-immunized naive mice. Co-staining for PrP
(Cy5-labeled POM2 antibody) and CD19 (PE-labeled anti-CD19
antibody) in representative samples. Four mice per group were
analyzed. Numbers in the diagram indicate averages (as
percentages) 6 standard deviation. Blood from a PrP deficient
mouse (Prnp
2/2) served as negative control.
Found at: doi:10.1371/journal.pone.0007160.s003 (1.01 MB TIF)
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